Mon, Mar 2, 2015, 8:24 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • ametrosixual ametrosixual Jul 1, 2013 3:18 PM Flag

    UPDATE: UBS To Downgrade Insmed On Phase 3 Fail


    UPDATE: UBS Starts Insmed (INSM) at Buy
    June 18, 2013 6:42 AM EDT Send to a Friend

    (Updated - June 18, 2013 10:55 AM EDT)

    UBS initiated coverage on Insmed (NASDAQ: INSM) with a Buy rating and a price target of $17.50. Analyst Matthew Harrison is positive on the company's pipeline.

    "We believe that Arikace, Insmed’s key late-stage clinical asset, has a solid chance of success in its primary indication of cystic fibrosis (CF) patients with underlying lung infections given its differentiated lipid delivery technology and its once-daily dosing (compared to 2-3x daily for the competition). Further, we believe that the Non-tuberculous mycobacteria (NTM) opportunity is underappreciated by the Street and could provide a second leg to growth with Phase II data by YE 2013," said Harrison.

    Shares of Insmed closed at $12.78 yesterday, with a 52 week range of $2.86-$14.30.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
18.78+0.24(+1.29%)Mar 2 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
SBA Communications Corp.
NASDAQMon, Mar 2, 2015 4:00 PM EST
NXP Semiconductors NV
NASDAQMon, Mar 2, 2015 4:00 PM EST